As of 2026-02-15, the EV/EBITDA ratio of Syros Pharmaceuticals Inc (SYRS) is 0.18. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SYRS's latest enterprise value is -17.18 mil USD. SYRS's TTM EBITDA according to its financial statements is -95.71 mil USD. Dividing these 2 quantities gives us the above SYRS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.8x - 14.8x | 14.8x |
| Forward P/E multiples | 11.6x - 20.5x | 16.0x |
| Fair Price | (12,224.83) - (12,224.83) | (12,747.42) |
| Upside | -10430838.5% - -10430838.5% | -10876737.9% |
| Date | EV/EBITDA |
| 2026-02-11 | 0.18 |
| 2026-02-10 | 0.18 |
| 2026-02-09 | 0.18 |
| 2026-02-06 | 0.18 |
| 2026-02-05 | 0.18 |
| 2026-02-04 | 0.18 |
| 2026-02-03 | 0.18 |
| 2026-02-02 | 0.18 |
| 2026-01-30 | 0.18 |
| 2026-01-29 | 0.18 |
| 2026-01-28 | 0.18 |
| 2026-01-27 | 0.18 |
| 2026-01-26 | 0.18 |
| 2026-01-23 | 0.18 |
| 2026-01-22 | 0.18 |
| 2026-01-21 | 0.18 |
| 2026-01-20 | 0.18 |
| 2026-01-16 | 0.18 |
| 2026-01-15 | 0.18 |
| 2026-01-14 | 0.18 |
| 2026-01-13 | 0.18 |
| 2026-01-12 | 0.18 |
| 2026-01-09 | 0.18 |
| 2026-01-08 | 0.18 |
| 2026-01-07 | 0.18 |
| 2026-01-06 | 0.18 |
| 2026-01-05 | 0.18 |
| 2026-01-02 | 0.18 |
| 2025-12-31 | 0.18 |
| 2025-12-30 | 0.18 |
| 2025-12-29 | 0.18 |
| 2025-12-26 | 0.18 |
| 2025-12-24 | 0.18 |
| 2025-12-23 | 0.18 |
| 2025-12-22 | 0.18 |
| 2025-12-19 | 0.18 |
| 2025-12-18 | 0.18 |
| 2025-12-17 | 0.18 |
| 2025-12-16 | 0.18 |
| 2025-12-15 | 0.18 |
| 2025-12-12 | 0.18 |
| 2025-12-11 | 0.18 |
| 2025-12-10 | 0.18 |
| 2025-12-09 | 0.18 |
| 2025-12-08 | 0.18 |
| 2025-12-05 | 0.18 |
| 2025-12-04 | 0.18 |
| 2025-12-03 | 0.18 |
| 2025-12-02 | 0.18 |
| 2025-12-01 | 0.18 |